Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) Income from Continuing Operations (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Income from Continuing Operations for 12 consecutive years, with 1154000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 2.37% year-over-year to 1154000.0, compared with a TTM value of 5163000.0 through Sep 2025, down 216.73%, and an annual FY2024 reading of 4317000.0, up 18.99% over the prior year.
  • Income from Continuing Operations was 1154000.0 for Q3 2025 at Arcadia Biosciences, down from 501000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 5213000.0 in Q4 2023 and bottomed at 16062000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 2840894.74, with a median of 1588000.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations tumbled 286.92% in 2021, then soared 603.67% in 2023.
  • Year by year, Income from Continuing Operations stood at 16062000.0 in 2021, then surged by 93.56% to 1035000.0 in 2022, then skyrocketed by 603.67% to 5213000.0 in 2023, then tumbled by 177.46% to 4038000.0 in 2024, then soared by 71.42% to 1154000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for RKDA at 1154000.0 in Q3 2025, 501000.0 in Q2 2025, and 530000.0 in Q1 2025.